SCHEMBL4816658

SCHEMBL4816658

[CH2]/C=C/c1cccc(-c2ccncc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 6/20 0.49
NOTUM Q6P988 1/20 0.45
MAPT P10636 2/20 0.44
PRKCI P41743 1/20 0.44
NPC1 O15118 1/20 0.44
GFER P55789 1/20 0.44
KIF11 P52732 1/20 0.44
CYP17A1 P05093 3/20 0.41
CYP11B1 P15538 3/20 0.41
CYP21A2 P08686 2/20 0.41
PRMT6 Q96LA8 1/20 0.41
CDK1 P06493 4/20 0.41
CDK4 P11802 4/20 0.41
CCNA2 P20248 4/20 0.41
CCND1 P24385 4/20 0.41
CDK2 P24941 4/20 0.41
CCND3 P30281 4/20 0.41
LMNA P02545 1/20 0.41
KDM1A O60341 1/20 0.37
QDPR P09417 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9320134 0.84 BCL2L1 (0.43) CHEK1CYP19A1
SCHEMBL9320139 0.84 BCL2L1 (0.43) CHEK1CYP19A1
SCHEMBL4822624 0.82 CYP2A6 (0.52) CHEK1MAPTCYP17A1CYP11B1PRMT6
SCHEMBL17127156 0.81 NOTUM (0.48) CHEK1NOTUMMAPTPRKCINPC1
SCHEMBL4814582 0.80 ATM (0.45) CHEK1MAPTNPC1GFERPIM2
SCHEMBL10022093 0.79 PTGS2 (0.50) CHEK1NOTUMMAPTPRKCIKIF11
SCHEMBL10022095 0.79 NOTUM (0.46) CHEK1NOTUMMAPTPRKCINPC1
SCHEMBL4820084 0.78 CYP17A1 (0.52) CHEK1NOTUMMAPTNPC1KIF11
SCHEMBL6655430 0.78 CLK4 (0.44) MAPTNPC1GFERKDM1APIM2
SCHEMBL302530 0.77 TRIM24 (0.56) CHEK1NOTUMMAPTPRKCIKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US claimed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US claimed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP claimed
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US disclosed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US disclosed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same BCL6, NR4A1, NR4A2 CHEK1 4512/4885NOTUM 1552/4885MAPT 4720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.